Skip to main content

Table 1 Baseline characteristics and concomitant diseases

From: Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease

Patient

GA at birth

AA at injection

Birthweight

Comcomitant diseases

1

24 5/7

OD: 37 3/7

500 g

apnea and bradycardia syndrome, persisten ductus arteriosus, RDS, pneumonia, kidney insufficiency, arterial hypotension, hyperbilirubinemia, anemia

OS: 32 6/7

2

24 5/7

OD 34 3/7

450 g

apnea and bradycardia syndrome, persisten ductus arteriosus, RDS, pneumonia, arterial hypotension, hyperbilirubinemia, anemia, hernia inguinalis, sepsis, neutropenia

3

24 4/7

OD: 34 4/7

665 g

apnea and bradycardia syndrome, , RDS, neonatal infection, urinary tract infection, intracerebral hemorrhage pneumonia, arterial hypotension, hyperbilirubinemia, anemia, bronchopulmonary dysplasia, kidney insufficiency

OS: 35 5/7

4

26 1/7

OS: 38 6/7

745 g

apnea and bradycardia syndrome, RDS, hyperbilirubinemia, anemia

  1. GA = gestational age; RDS = respiratory distress syndrome; AA = Adjusted age.